cyclase A, and is able to accelerate production of cyclic guanosine monophosphate, to a subject in a need of such treatment in an amount effective for treating said heart disease.

7. A method as set forth in claim 6, wherein the heart disease based on cardiac hypertrophy is chronic heart failure.

Sub B2 8. A method as set forth in claim 6, wherein the substance that acts on the natriuretic peptide receptor, guanylyl cyclase A, and is able to accelerate production of cyclic guanosine monophosphate is a natriuretic peptide.

9. A method as set forth in claim 8, wherein the natriuretic peptide is atrial natriuretic peptide.

10. A method as set forth in claim 8, wherein the natriuretic peptide is brain natriuretic peptide.

11. A method as set forth in claim 6, wherein said substance is in a form of a pharmacologically acceptable salt.

12. A method as set forth in claim 6, wherein said substance is orally administered.

13. A method as set forth in claim 6, wherein said substance is administered by a non-oral administration selected from the group consisting of intravenous administration, intramuscular administration and subcutaneous administration.

14. A method as set forth in claim 6, wherein said substance is administered in a form selected from the group consisting of a microcapsule preparation, a suppository, a nasal spray and a sublingual lozenge.

15. A pharmaceutical composition as set forth in claim 1, wherein said substance is in a form of a pharmacologically acceptable salt.

16. A pharmaceutical composition as set forth in claim 1, further comprising a pharmacologically acceptable carrier, vehicle or diluent.

17. A pharmaceutical composition as set forth in claim 1, in a form suitable for oral administration.

18. A pharmaceutical composition as set forth in claim 1, in a form selected from the group consisting of a microcapsule preparation, a suppository, a nasal spray and a sublingual lozenge.

19. A pharmaceutical composition as set forth in claim, in a form suitable for a non-oral administration selected from the group consisting of intravenous administration, intramuscular administration and subcutaneous administration.

20. A method for producing a pharmaceutical composition for treatment of heart disease based on cardiac hypertrophy comprising adding a substance that acts on the natriuretic peptide receptor, guanylyl cyclase A, and is able to accelerate production of cyclic guanosine monophosphate, to a pharmacologically acceptable carrier, vehicle or diluent.--

REMARKS

Prior to or contemporaneous with the examination of the above-identified U.S. patent application, please amend claims 3-5 and add new claims 6 -20. Support for these new claims may be found at the very least at pages 6-7 of the application. No new matter is being added.

Favorable action in the form of a Notice of Allowance is respectfully requested. Such action is respectfully believed to be in order.